Mabion SA
WSE:MAB
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
11.4
22.6
|
Price Target |
|
We'll email you a reminder when the closing price reaches PLN.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one MAB stock under the Base Case scenario is 16.19 PLN. Compared to the current market price of 11.4 PLN, Mabion SA is Undervalued by 30%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Mabion SA
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for MAB cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Mabion SA
Balance Sheet Decomposition
Mabion SA
Current Assets | 75.1m |
Cash & Short-Term Investments | 50.2m |
Receivables | 14.4m |
Other Current Assets | 10.4m |
Non-Current Assets | 121.3m |
PP&E | 115.9m |
Intangibles | 366k |
Other Non-Current Assets | 5m |
Current Liabilities | 41.2m |
Accounts Payable | 2.4m |
Accrued Liabilities | 3.3m |
Other Current Liabilities | 35.4m |
Non-Current Liabilities | 9.5m |
Long-Term Debt | 2.3m |
Other Non-Current Liabilities | 7.2m |
Earnings Waterfall
Mabion SA
Revenue
|
139.9m
PLN
|
Cost of Revenue
|
-30.4m
PLN
|
Gross Profit
|
109.5m
PLN
|
Operating Expenses
|
-52.5m
PLN
|
Operating Income
|
57m
PLN
|
Other Expenses
|
-19.6m
PLN
|
Net Income
|
37.4m
PLN
|
Free Cash Flow Analysis
Mabion SA
PLN | |
Free Cash Flow | PLN |
MAB Profitability Score
Profitability Due Diligence
Mabion SA's profitability score is 54/100. The higher the profitability score, the more profitable the company is.
Score
Mabion SA's profitability score is 54/100. The higher the profitability score, the more profitable the company is.
MAB Solvency Score
Solvency Due Diligence
Mabion SA's solvency score is 78/100. The higher the solvency score, the more solvent the company is.
Score
Mabion SA's solvency score is 78/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MAB Price Targets Summary
Mabion SA
According to Wall Street analysts, the average 1-year price target for MAB is 15.81 PLN with a low forecast of 13.13 PLN and a high forecast of 19.43 PLN.
Dividends
Current shareholder yield for MAB is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Mabion SA is a biotechnology company, which engages in the development and manufacture of biotech drugs. The company is headquartered in Konstantynow Lodzki, Woj. Lodzkie and currently employs 213 full-time employees. The company went IPO on 2010-08-10. Mabion SA was founded by four pharmaceutical companies, including Celon Pharma Ltd, Polfarmex Co, Genexo Ltd and IBSS Biomed Co, as well as two companies focused on research and development in biotechnology field, including BioCentrum Ltd and Biotech Consulting Ltd. The firm specializes in the humanized monoclonal antibodies (mAbs) technology, a new generation of biotechnological drugs. The company focuses on oncology drugs used to treat blood cancer, lymphomas and leukemias, rheumatoid arthrisis, as well as breast cancer. The company operates its own Research and Development Center in the Special Economical Zone in Lodz, Poland.
Contact
IPO
Employees
Officers
The intrinsic value of one MAB stock under the Base Case scenario is 16.19 PLN.
Compared to the current market price of 11.4 PLN, Mabion SA is Undervalued by 30%.